This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cabometyx
  • /
  • Cabozantinib Versus Sunitinib for Metastatic Varia...
Clinical trial

Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma

Read time: 3 mins
Last updated:15th May 2018
Identifier: NCT03541902

The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer.

This is an investigational study. Cabozantinib and sunitinib are both FDA approved and commercially available for the treatment of advanced kidney cancer, including vhRCC.

The study doctor can explain how the study drugs are designed to work.

Up to 84 participants will be enrolled in this study. All will take part at MD Anderson.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cabosun II: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma
Actual Study Start Date: May 15, 2018
Estimated Primary Completion Date: July 2020
Estimated Study Completion Date: July 2020

Arm:
- Experimental:
Cabozantinib Group
- Experimental: Sunitinib Group

Category Value
Date last updated at source 2018-07-16
Study type(s) Interventional
Expected enrolment 84
Study start date 2018-05-15
Estimated primary completion date 2020-07-01

View full details